Subcutaneous Immunoglobulin (SCIG) Market Insights, Forecast, Growth, Trends 2024-2033

The subcutaneous immunoglobulin (scig) global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Subcutaneous Immunoglobulin (SCIG) Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size –

The subcutaneous immunoglobulin  market size has grown rapidly in recent years. It will grow from $11.19 billion in 2023 to $12.72 billion in 2024 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to the increased prevalence of immunodeficiency disorders, rise in the patient preference for home-based care, enhanced therapeutic efficacy, growth in the awareness and diagnosis rates, growth in the favorable reimbursement policies.

The subcutaneous immunoglobulin  market size is expected to see rapid growth in the next few years. It will grow to $21.38 billion in 2028 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to the growing prevalence of neurological disorders, increasing prevalence of autoimmune diseases, rising awareness and acceptance of immunoglobulin therapy, expanding applications in neurology and dermatology, expansion of healthcare facilities. Major trends in the forecast period include advancements in drug delivery systems, increasing demand for home infusion therapies, developments in antibody therapy, Innovations in formulations, and Innovations in SCIG.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

Scope Of Subcutaneous Immunoglobulin (SCIG) Market

The Business Research Company’s reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Subcutaneous Immunoglobulin (SCIG) Market Overview

Market Drivers –

The subcutaneous immunoglobulin  market size has grown rapidly in recent years. It will grow from $11.19 billion in 2023 to $12.72 billion in 2024 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to the increased prevalence of immunodeficiency disorders, rise in the patient preference for home-based care, enhanced therapeutic efficacy, growth in the awareness and diagnosis rates, growth in the favorable reimbursement policies.

The subcutaneous immunoglobulin  market size is expected to see rapid growth in the next few years. It will grow to $21.38 billion in 2028 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to the growing prevalence of neurological disorders, increasing prevalence of autoimmune diseases, rising awareness and acceptance of immunoglobulin therapy, expanding applications in neurology and dermatology, expansion of healthcare facilities. Major trends in the forecast period include advancements in drug delivery systems, increasing demand for home infusion therapies, developments in antibody therapy, Innovations in formulations, and Innovations in SCIG.

Market Trends –

Major companies operating in the subcutaneous immunoglobulin market are developing subcutaneous human-klhw, a unique formulation containing human immune globulins (Ig) that strengthens the immune system. Subcutaneous human-klhw is used for subcutaneous administration, developed for treating primary immunodeficiency diseases in human body. For instance, in March 2022, Grifols S.A., a Spain-based pharmaceutical company, launched XEMBIFY 20% subcutaneous immunoglobulin (SCIG). It is specifically designed to treat primary immunodeficiency, meeting a significant medical need for people with weakened immune systems. XEMBIFY is a ready-to-use formulation that simplifies the treatment process and increases patient convenience. It is stable at room temperature for up to 24 months, avoiding the need for refrigeration during storage and transportation, which can be extremely useful in a variety of healthcare settings.

The subcutaneous immunoglobulin (SCIG) market covered in this report is segmented –

1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)

2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications

3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses

Get an inside scoop of the subcutaneous immunoglobulin (scig) market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp

Regional Insights –

North America was the largest region in the subcutaneous immunoglobulin  market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Key Companies –

Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy’s Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc., Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc

Table of Contents

1. Executive Summary
2. Subcutaneous Immunoglobulin (SCIG) Market Report Structure
3. Subcutaneous Immunoglobulin (SCIG) Market Trends And Strategies
4. Subcutaneous Immunoglobulin (SCIG) Market – Macro Economic Scenario
5. Subcutaneous Immunoglobulin (SCIG) Market Size And Growth

…..

27. Subcutaneous Immunoglobulin (SCIG) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

 

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model